Pharmaceutical Technology22h
FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
Pharmaceutical Technology23h
FDA approves Azurity Pharmaceuticals’ Danziten for CML treatment
The US Food and Drug Administration (FDA) has approved Azurity Pharmaceuticals’ Danziten (nilotinib), the first and only ...
Pharmaceutical Technology22h
AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefit
AC Immune’s Phase II trial showed an increase in anti-a-syn antibodies following treatment with the Parkinson’s disease ...
Pharmaceutical Technology14h
Merative MarketScan
The FDA has released final draft recommendations for using real-world data and evidence in drug development.